clinical trial · NCT05787496
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic LeukemiaRelapsed or Refractory Myelodysplastic SyndromeNC525
brief summary
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
started
Feb 28, 2023
primary completion
Jan 31, 2025
completion
Jan 31, 2025
last updated
Jan 28, 2026
official title
A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol